The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The decision is based on the phase 3 DESTINY-Breast11 trial
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Subscribe To Our Newsletter & Stay Updated
